Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients.

Authors

• Casado, José L¹
• Vizcarra, Pilar¹
• Blanco, José L²
• Montejano, Rocío³
• Negredo, Eugenia⁴
• Espinosa, Nuria⁵
• Montero, Marta⁶
• Mena, Alvaro⁷
• Palacios, Rosario⁸
• Lopez, Juan C⁹
• Vergas, Jorge¹⁰
• Galindo, Maria J¹¹
• Cabello, Alfonso¹²
• Deltoro, Miguel García¹³
• Diaz De Santiago, Alberto¹⁴

• ¹ Hospital Universitario Ramón y Cajal, Madrid, Spain. , (Spain)
• ² Hospital Clínic de Barcelona, Barcelona, Spain. , (Spain)
• ³ Hospital Universitario La Paz, Madrid, Spain. , (Spain)
• ⁴ Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. , (Spain)
• ⁵ Hospital Universitario Virgen del Rocío, Sevilla, Spain. , (Spain)
• ⁶ Hospital Universitario La Fe, Valencia, Spain. , (Spain)
• ⁷ Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain. , (Spain)
• ⁸ Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. , (Spain)
• ⁹ Hospital General Universitario Gregorio Marañón, Madrid, Spain. , (Spain)
• ¹⁰ Hospital Clínico San Carlos, Madrid, Spain. , (Spain)
• ¹¹ Hospital Clínico Universitario de Valencia, Valencia, Spain. , (Spain)
• ¹² Fundación Jimenez Diaz, Madrid, Spain. , (Spain)
• ¹³ Hospital General Universitario de Valencia, Valencia, Spain. , (Spain)
• ¹⁴ Hospital Universitario Puerta de Hierro, Madrid, Spain. , (Spain)

Type

Published Article

Journal

International Journal of STD & AIDS

Publisher

SAGE Publications

Publication Date

Apr 01, 2020

Volume

31

Issue

5

Pages

467–473

Identifiers

DOI: 10.1177/0956462419896478

PMID: 32138618

Source

Medline

Keywords

• Dual Therapy
• Darunavir
• Raltegravir
• Resistance
• Simplification
• Switching
• Toxicity

Language

English

License

Unknown